Table 3 Subgroup analyses for the effect of acupuncture on neurogenesis after ischemic stroke.

From: Acupuncture for neurogenesis in experimental ischemic stroke: a systematic review and meta-analysis

Brdu (7d)

Nestin (7d)

PSA-NCAM (7d)

NeuN (14d)

Groups

n

MD [95%CI]

P

Ad R2(%)

n

MD [95%CI]

P

Ad R2(%)

n

MD [95%CI]

P

n

MD [95%CI]

P

All trials

19

32.85 [20.78,44.91]

  

16

37.39 [24.69, 50.09]

  

6

30.90 [17.39, 44.40]

 

6

22.62 [15.16, 30.07]

 

Encephalic region

  

<0.001

N/A

  

<0.001

1.21

  

0.15

  

<0.001

SVZ

10

31.64 [30.61, 32.67]

  

9

56.82 [17.75, 95.89]

  

3

61.72 [21.82, 101.61]

 

3

4.25 [3.34, 5.17]

 

SGZ

9

11.11 [10.42, 11.79]

  

6

13.18 [7.65, 18.71]

  

5

30.42 [16.12, 44.72]

 

3

10.26 [9.02, 11.51]

 

Species

  

0.01

14.33

  

0.006

1.99

  

<0.001

  

0.22

SD rats

10

18.80 [12.11, 25.50]

  

6

11.70 [6.64, 16.77]

  

5

1.41 [0.14, 2.67]

 

3

6.77 [5.77, 7.76]

 

Wistar rats

9

48.23 [26.68, 69.78]

  

10

48.01 [22.56, 73.47]

  

3

17.54 [14.27, 20.81]

 

3

5.85 [4.75, 6.95]

 

MCAO

  

<0.001

23.17

  

0.14

N/A

  

<0.001

  

<0.001

Permanent

4

7.79 [4.06, 11.52]

  

4

19.38 [11.69, 27.08]

  

2

9.29 [2.02, 16.57]

 

1

1.07 −1.39, 3.53]

 

Transient

14

36.01 [24.63, 47.38]

  

9

33.10 [13.99, 52.21]

  

4

44.19 [26.11, 62.26]

 

4

37.50 [23.29, 51.71]

 

NR

1

89.50 [87.14, 91.86]

  

3

61.65 [8.51, 114.78]

  

/

/

 

/

/

 

Anesthetic

  

<0.001

N/A

  

<0.001

6.22

  

N/A

  

N/A

Chloralhydrate

16

13.73 [13.09, 14.37]

  

12

11.43 [10.45, 12.41]

  

6

30.90 [17.39, 44.40]

 

6

22.62 [15.16, 30.07]

 

Pentobarbital sodium

3

31.28 [30.04, 32.52]

  

2

17.98 [16.66, 19.30]

  

/

/

 

/

/

 

NR

/

/

  

2

15.84 [14.41, 17.28]

  

/

/

 

/

/

 

Weight (gram)

  

0.79

N/A

  

0.001

N/A

  

0.11

  

0.001

 > 300

3

40.02 −20.62, 100.67]

  

2

13.06 [10.92, 15.20]

  

2

20.32 [11.49, 29.15]

 

2

6.35 [2.97, 9.73]

 

< = 300

16

31.51 [18.50, 44.51]

  

12

45.40 [26.02, 64.78]

  

4

36.07 [19.18, 52.96]

 

4

22.28 [13.17, 31.38]

 

NR

/

/

  

2

15.84 [14.41, 17.28]

  

/

/

 

/

/

 

Duration of treatment (min)

  

<0.001

31.16

  

<0.001

7.70

  

N/A

  

<0.001

 > 15

14

32.85 [20.78, 44.91]

  

10

8.18 [7.37, 9.00]

  

6

30.90 [17.39, 44.40]

  

3.56 [2.37, 4.75]

 

< = 15

5

64.82 [45.12, 84.53]

  

6

29.46 [28.17, 30.76]

  

/

/

  

5.33 [4.68, 5.99]

 

Baseline

  

0.01

24.43

  

0.02

48.78

  

0.01

  

N/A

mean > 100

11

44.17 [23.32, 65.01]

  

4

95.65 [31.27, 160.04]

  

3

59.03 [21.78, 96.29]

 

6

2.44 [1.23, 3.65]

 

mean < = 100

8

16.21 [10.56, 21.85]

  

12

17.35 [12.91, 21.79]

  

3

10.00 [−1.67, 21.67]

 

/

/

 
  1. P value for test for subgroup differences. Adjusted R2 for study characteristics accounting for heterogeneity. Ad, adjusted; MCAO, middle cerebral artery occlusion; N/A: not acquired; NR, no report; SGZ, subgranular zone; SVZ, subventricular zone.